A car­dio­vas­cu­lar cell ther­a­py play­er grabs $54M for a new be­gin­ning — where next-gen CAR-T ap­proach fea­tures promi­nent­ly

Be­fore the ad­vent of CAR-T, the term cell ther­a­py con­jured up very dif­fer­ent im­ages. Sure, there were can­cer im­munother­a­pies like Den­dreon’s Provenge, but more com­mon were the var­i­ous fla­vors of stem cell ther­a­pies and cell trans­plan­ta­tion.

None of that has gone away, even if they’ve been nudged out of the spot­light — and a lit­tle biotech has gar­nered $54 mil­lion (£40 mil­lion) to show that both the old and new ideas of cell (and gene) ther­a­py can mesh to­geth­er to form a spe­cial breed of plat­form com­pa­ny.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.